Eterna Therapeutics receives Nasdaq delisting notice for stockholders' equity below $2.5M minimum

Ernexa Therapeutics Inc.

Stockholders' equity was $2.2M as of Dec 31, 2024, below the $2.5M minimum required by Nasdaq Listing Rule 5550(b)(1).
Company must submit a compliance plan to Nasdaq by May 3, 2024.
If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.
No immediate effect on listing; common stock continues trading under ERNA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.